Anixa Biosciences, Inc.

NASDAQ:ANIX

Biotechnology

Healthcare
$2.71 +3.72%

+$0.10 today

Market cap
$94.21M
Beta
0.60
P/E (TTM)
-9.3
EPS (TTM)
-$0.30
52W Low $2.32High $5.46

Volume 0.29M

Average 0.12M

ANIX Operating Cash Flow

Cash generated by the company's core business operations during the period.

Anixa Biosciences, Inc.NASDAQ: ANIX

Operating Cash Flow · Q2 FY2026 · quarter ended Apr 2026

Operating cash flow growth accelerates

Q2 FY2026 operating cash flow of $1.74M (cash outflow) rose 15.8% year over year, ahead of the -10.8% change in trailing-twelve-month operating cash flow. Sequentially, it fell 33.3% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.

Context

  • Operating cash flow grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +15.8% holds above the trailing-twelve-month pace of -10.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterApr 2026
-$1.74M-33.3% QoQ
Last fiscal yearOct 2025
-$7.17M-2.2% YoY
LTMApr 2026
-$7.12M-10.8% YoY
Operating Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.8%——
1 year-2.2%——
3-year CAGR+3.4%——
5-year CAGR——
10-year CAGR——

Operating Cash Flow history

USD · from the cash flow

Latest · FY2025
(7.17M) USD
Year-over-year change
+2.2%

Operating Cash Flow vs competitors

How ANIX compares with its peers on the latest reported figures

  • ANIX's LTM Apr 2026 operating cash flow of $7.12M is the smallest of the 10 companies compared; the peer median is $38.99M.
  • Its year-over-year change of -10.8% is the 7th highest of 9, against a peer median of +3.0%.
  • Over three fiscal years its annual growth of +3.4% compares with a peer median of -0.4%.
ANIX Competitors Peer median
Operating Cash Flow for ANIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$105.55M +3.0%+48.7%—
AGENAgenus Inc.LTM Mar 2026$87.53M -39.9%-3.4%70.7%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$83.35M -18.4%-25.7%—
SEERSeer, Inc.LTM Mar 2026$48.47M +3.0%-9.9%322.3%
IRDOpus Genetics, Inc.LTM Mar 2026$38.99M +35.1%—325.3%
HURATuHURA Biosciences, Inc.LTM Mar 2026$27.3M —+54.4%—
ACTUActuate Therapeutics IncLTM Mar 2026$19.78M -6.8%+2.6%—
ENTXEntera Bio Ltd.LTM Mar 2026$9.5M +49.4%-16.1%—
SPROSpero Therapeutics, Inc.LTM Mar 2026$7.24M +121.7%+17.8%13.2%
ANIXAnixa Biosciences, Inc.LTM Apr 2026$7.12M -10.8%+3.4%—
Peer median (excluding ANIX) $38.99M+3.0%-0.4%196.5%

Competitors are the stored peer set for ANIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Oct 2021
FY2022
Oct 2022
FY2023
Oct 2023
FY2024
Oct 2024
FY2025
Oct 2025
Net Income(13.13M)(13.77M)(9.93M)(12.7M)(11.03M)
Depreciation & Amortization60K42K46K37K(107K)
Deferred Income Tax00000
Stock-Based Compensation7.5M6M4.42M4.42M3.68M
Change in Working Capital78K485K(1.06M)526K152K
Accounts Receivables0(29K)(224K)97K173K
Inventory00000
Accounts Payables(96K)129K(59K)319K(360K)
Other Working Capital174K385K(777K)110K339K
Other Non-Cash Items549K752K313K380K129K
Operating Cash Flow(4.94M)(6.49M)(6.21M)(7.34M)(7.17M)
Capital Expenditures00000
Acquisitions (Net)7K0000
Purchases of Investments(16.5M)(22.49M)(44.41M)(63.77M)(44.36M)
Sales of Investments12.54M11.76M38.81M68.05M49.23M
Other Investing Activities35K0000
Investing Cash Flow(3.92M)(10.73M)(5.6M)4.28M4.87M
Debt Repayment00000
Common Stock Issued31.13M002.96M2.28M
Common Stock Repurchased000(6K)0
Dividends Paid00000
Other Financing Activities440K452K366K466K0
Financing Cash Flow31.57M452K366K3.42M2.28M
Effect of Forex Changes00000
Net Change in Cash22.71M(16.77M)(11.45M)356K(27K)
Free Cash Flow(4.94M)(6.49M)(6.21M)(7.34M)(7.17M)

Anixa Biosciences, Inc.

NASDAQ:ANIX

Intrinsic Alpha fair value

Locked

Current Price

$2.71

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.